Efficacy of Sparex in the management of intestinal motility disorders

Irritable bowel syndrome (IBS) is one of the most common functional bowel diseases. What is more, a number of digestive diseases are characterized by symptoms similar to those observed in IBS. The principles of treatment of IBS and IBS-related disorders are same. The key symptom of IBS - abdominal pain - is developed as a result of spasmodic or hyperkinetic dyskinesia, so the main group of drugs to be used in the treatment are antispasmodics. Preference is given to selective antispasmodics. Sparex is a national generic of the selective intestinal antispasmodic mebeverine hydrochloride which has been known since 1965, and is characterized by the most affordable price among analogues. The study which included 48 patients demonstrated high efficacy of Sparex administered for 4 weeks in a dosage of 200 mg twice daily for relief of pain, flatulence and stool normalization both in IBS and IBS-related disorders. Good and satisfactory results evaluated by a 3-point scale were achieved in 87.5% of patients. The results allowed to conclude that the medicine, apart from its strong antispasmodic effect, also provided a eukinetic action - normalization of the transit of chyme in the intestine both in constipation and diarrhea. Normalization of stool was observed in 77.2% of patients with both constipation and diarrhea, and in the rest of patients the severity of stool disorders decreased by more than 1 point. In the course of the study, no side effects were observed while taking Sparex.

синдром раздраженного кишечника, (СРК), СРК-подобные нарушения, абдоминальная боль, мебеверина гидрохлорид, Спарекс, irritable bowel syndrome (IBS), IBS-related disorders, abdominal pain, mebeverine hydrochloride, Sparex

1. Drossman DA, CamiLLeri M, Mayer EA, Whitehead WE. AGA technical review on irritable boweL syndrome. Gastroenterology, 2002, 123: 2108-31.

2. Farrokhyar F, MarshaLL JK, Easterbrook B et aL. FunctionaL GastrointestinaL Disorders and Mood Disorders in Patients with Inactive InfLammatory BoweL Disease: PrevaLence and Impact on HeaLth. Inflamm Bowel Dis, 2006, 12(1): 38-45.

3. Esposito I, de Leone A, Di Gregorio G, Giaquinto S, de Magistris L, Ferrieri A, RiegLer G. Breath test for differentiaL diagnosis between smaLL intestinaL bacteriaL overgrowth and irritabLe boweL disease: An observation on nonabsorba-bLe antibiotics. World J Gastroenterol., 2007, 13(45): 6016-6021.

4. CamiLLeri M, Lasch K and Zhou W. IrritabLe boweL syndrome: Methods, mechanisms, and pathophysioLogy. The confLuence of increased permeabiLity, infLammation, and pain in irritabLe boweL syndrome. Am J Physiol. Gastrointest. Liver Physiol., 2012, 303: 775-785.

5. SpiLLer R and Lam C. An update on post-infectious irritabLe boweL syndrome: RoLe of genetics, immune activation, serotonin and aLtered microbiome. J Neurogastroenterol Motil., 2012, 18: 258-268.

6. Andresen V, Lowe B, Broicher W, RiegeL B, Fraedrich K, von WuLffen M et aL. Post-infectious irritabLe boweL syndrome (PI-IBS) after infection with Shiga-Like toxin-producing Escherichia coLi (STEC) O104:H4: A cohort study with prospective foLLow-up. United European Gastroenterology Journal, 2016, 4(1): 121-131.

7. Drossman DA. The FunctionaL GastrointestinaL Disorders and the Rome III Process. Gastroenterology, 2006, 130(5).

8. Яковенко Э.П., Агафонова Н.А., Яковенко А.В., Иванов А.Н., Прянишникова А.С., Краснолобова Л.П. Роль моторных нарушений в механизмах формирования клинических проявлений синдрома раздраженной кишки (СРК) и СРК-подобных нарушений. Вопросы терапии. Consilium Medicum, 2011, 1: 69-73.

9. Whitehead WE, CroweLL MD, Davidoff AL et aL. Pain from rectaL distension in women with irritabLe boweL syndrome. Dig. Dis. Sci.,1997, 42: 796-804.

10. Bueno L, Fioramonti J, DeLvaux M et aL. Mediators and pharmacoLogy of visceraL sensitivity: from basic to cLinicaL investigations. GastroenteroLogy 1997, 112:1714-43.

11. Ramkumar D, Rao SS. Efficacy and safety of traditionaL medicaL therapies for chronic constipation: systematic review. Am J Gastroenterol., 2005, 100: 936-971.

12. Poynard T, Naveau S, Mory B, Chaput JC. Meta-anaLysis of smooth muscLe reLaxants in the treatment of irritabLe boweL syndrome. Aliment. Pharmacol. Ther., 1994, 8: 499-510.

13. Thasman-Jones C. Mebeverine in patient with the irritabLe coLon syndrom: doubLe bLind study. N. Z. Med. J. 1973, 77: 232-235.

14. GriLLage MG, Nankani JN et aL. A randomized, doubLe-bLind study of mebeverine versus dicy-cLomine in the treatment of functionaL abdominaL pain in young aduLts. Br J Clin. Pract., 1990, 44: 176-179.

15. Tudor GJ. A generaL practice study to compare aLverine citrate with mebeverine hydrocLoride in the treatment of irritabLe boweL syndrome. Br J Clin. Pract., 1986, 40: 276-278.

16. Evans PR, Bak Y-T, KeLLow JE. Mebeverine aLters smaLL boweL motiLity in irritabLe boweL syndrome. Aliment. Pharmacol. Ther, 1996, 10: 787-793.

17. ConneL AM. PhysioLogicaL and cLinicaL assessment of the effect of the muscuLotropic agent mebeverin on the human coLon. Br. Med. J. 1965, 2: 848-851.

18. Yakovenko E.P., Agafonova N.A., Yakovenko A.V., Ivanov A.N., Pryanishnikova A.S., Krasnolobova L.P. The role of motility disorders in the mechanisms of formation of clinical manifestations of irritable bowel syndrome (IBS) and IBS-related disorders. Voprosy Terapii. Consilium Medicum, 2011, 1: 69-73